Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.40 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495921 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL3495919 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29498158 | 0.93 | MMP8 (0.43) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL31410871 | 0.91 | ALDH1A1 (0.39) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29906328 | 0.91 | EGFR (0.42) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29250266 | 0.89 | ALDH1A1 (0.37) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL29394144 | 0.89 | MAPT (0.44) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL30051701 | 0.87 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5176099 | 0.87 | CTSL (0.38) | ALDH1A1MAPTLAP3CTSLCTSB | |
| SCHEMBL7201733 | 0.87 | CTSL (0.38) | ALDH1A1MAPTLAP3CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118079030-A | Drug-loaded polymer nano micelle and preparation method and application thereof | 郑州大学 | 2024-05-28 | — | — | CN | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| CN-104755482-A | Functionalized 9-bromo-camptothecin derivatives | NERVIANO MEDICAL SCIENCES SRL | 2015-07-01 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250257338-A1 | GLYCOPROTEIN HAVING REDUCED NUMBER OF MANNOSE-6-PHOSPHATES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-4512892-A1 | GLYCOPROTEIN HAVING REDUCED NUMBER OF MANNOSE-6-PHOSPHATES | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
| CN-118079030-A | Drug-loaded polymer nano micelle and preparation method and application thereof | 郑州大学 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023204202-A1 | GLYCOPROTEIN HAVING REDUCED NUMBER OF MANNOSE-6-PHOSPHATES | ＪＣＲファーマ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| CN-110003337-B | IL17RA single domain antibody, nucleic acid and kit | 深圳普瑞金生物药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-104755482-A | Functionalized 9-bromo-camptothecin derivatives | NERVIANO MEDICAL SCIENCES SRL | 2015-07-01 | — | — | CN | disclosed |
| EP-1436317-A1 | MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024995-A1 | MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF | TRIPEP AB (SE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885MAPT 3330/4885LMNA 1538/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885MAPT 4191/4885LMNA 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.